June 09, 2022
Article
Sanofi and Regeneron Pharmaceuticals, Inc announced the FDA approval of dupilumab. It is now the first biologic medicine for children from 6 months to 5 years old with moderate to severe atopic dermatitis.
June 03, 2022
Regeneron Pharmaceuticals Inc came to an agreement to buy the drug from Sanofi for up to $1.1 billion.
May 16, 2022
UCB announced the FDA issued a CRL that stated that the FDA cannot approve the BLA in its current form.
May 10, 2022
Ruxolitinib cream 1.5% may soon be the first FDA-approved treatment for repigmentation of vitiligo. Experts share what dermatologists need to know regarding efficacy, safety, and cost of this topical drug.
May 02, 2022
An American Academy of Dermatology survey found that more Americans say sun protection is more important than 5 years ago, but don’t understand how to protect themselves.
April 28, 2022
Sol-Gel Technologies and Galderma announced the FDA approval of the 5% benzoyl peroxide, cream for the treatment of inflammatory lesions of rosacea.